Melanie Jay, MD, MS, is a professor of medicine and population health at NYU Langone Health and a physician investigator specializing in obesity
Weight loss outcomes in SURPASS-1 were equally impressive, with mean reductions of 7.0 kg, 7.8 kg, and 9.5 kg for the three tirzepatide doses, respectively, compared to 0.7 kg weight loss with placebo
Key takeaways Headache wasnt reported as a side effect in Zepbounds studies
In Great Britain you can be assured of this by making sure your pharmacy is registered with the General Pharmaceutical Council (GPhC)
The differential regulation on these genes may be due to several factors
Semaglutide remains the most effective pharmacological weight loss intervention available in 2026